DeepMed Research

The Sidney Kimmel Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.hopkinsmedicine.org/kimmel_cancer_center

Clinical Trials

Pembrolizumab in Patients With Leptomeningeal Disease

Phase 2

Terminated

Conditions: Patients With Leptomeningeal Disease

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-03-27

Last Posted Date: 2021-01-26

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 13

Registration Number: NCT03091478

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Trial of Mistletoe Extract in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Helixor® M

First Posted Date: 2017-02-13

Last Posted Date: 2022-12-08

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 21

Registration Number: NCT03051477

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Phase 2

Active, not recruiting

Conditions: Prostate

Interventions: Drug: Olaparib

First Posted Date: 2017-02-08

Last Posted Date: 2024-07-03

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 51

Registration Number: NCT03047135

Locations: 🇺🇸
Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 1 locations

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

Phase 1

Active, not recruiting

Conditions: Gastric Cancer
Esophageal Cancer
GastroEsophageal Cancer

Interventions: Drug: Nivolumab
Drug: Relatlimab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation

First Posted Date: 2017-02-07

Last Posted Date: 2025-03-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 32

Registration Number: NCT03044613

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Alleghany Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸
Baylor University/ Charles A. Sammons Cancer Center, Dallas, Texas, United States

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Cabazitaxel
Drug: Clarithromycin

First Posted Date: 2017-02-06

Last Posted Date: 2020-02-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 4

Registration Number: NCT03043989

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide Acetate
Drug: Docetaxel
Drug: Bicalutamide
Radiation: Radiation
Drug: Abiraterone Acetate

First Posted Date: 2017-02-06

Last Posted Date: 2023-02-16

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 26

Registration Number: NCT03043807

Locations: 🇺🇸
Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Study of Stereotactic Radiotherapy for Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Radiation: Stereotactic Body Radiation Therapy SBRT

First Posted Date: 2017-02-06

Last Posted Date: 2023-05-31

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 40

Registration Number: NCT03043794

Locations: 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Simplifying Survivorship Care Planning

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Care Plan Only
Behavioral: Care Plan During a Visit
Behavioral: Care Plan During a Visit with an Additional Visit

First Posted Date: 2017-01-30

Last Posted Date: 2024-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 378

Registration Number: NCT03035773

Locations: 🇺🇸
Peninsula Regional Medical Center, Salisbury, Maryland, United States
🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Phase 2

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Epacadostat
Drug: Pembrolizumab
Biological: CRS-207
Drug: Cyclophosphamide
Biological: GVAX Pancreas Vaccine

First Posted Date: 2016-12-30

Last Posted Date: 2024-10-08

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 41

Registration Number: NCT03006302

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Bone marrow transplantation
Drug: Cytoxan
Drug: testosterone cypionate

First Posted Date: 2016-12-16

Last Posted Date: 2024-02-13

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 3

Registration Number: NCT02995330

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy